Clinical Trial Update: The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 [Phase 2, Phase 3]

View source ↗

Summary

This entry describes an ongoing Phase 2/Phase 3 trial evaluating empagliflozin for renal outcomes in cardiorenal syndrome type 1, with recruitment currently ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiorenal Syndrome Type

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: Chulalongkorn University | Conditions: Empagliflozin in Cardiorenal Syndrome Type 1 | Phase 2, Phase 3 | Status: RECRUITING